Trademark: 88900009
Word
ONCOGENUITY
Status
Pending
Status Code
730
Status Date
Tuesday, April 2, 2024
Serial Number
88900009
Mark Type
4000
Filing Date
Monday, May 4, 2020
Published for Opposition
Tuesday, August 8, 2023

Trademark Owner History
Oncogenuity, Inc. - Owner At Publication

Classifications
5 Pharmaceutical and medicinal preparations for the treatment of cancer and oncological conditions; Pharmaceuticals, namely, drug delivery agents in the form of compounds that facilitate delivery of injectable pharmaceutical preparations and in the form of subcutaneous compounds that provide controlled release, and in the form of injectable pharmaceuticals, powders, tablets, capsules, pills, caplets, liquid drops, sachets, spray, ointment, cream, gel, lotion, patch, inhaler, granule, film, suspension, infusion and suppository, capsules, and tablets of peptide nucleic acids for the treatment of cancer and oncological conditions; Oncological preparations, namely, pharmaceutical preparations for the detection, prevention, and treatment of cancer; Pharmaceutical and medicinal preparations for the treatment of cancer, cell transplants and cell transplant rejection, organ transplants and organ transplant rejection, angiogenesis, bacterial infection, peripheral blood stem cell mobilization, lymphoma, tissue regeneration, tissue repair, leukemia, drug-induced anemia, retrovirus, viral infections, hematopoietic deficit resulting from chemotherapy or radiation therapy, elevation of white blood cells; Stem cells for medical purposes; Synthetic peptides for the treatment of cancer and oncological conditions; Biological tissue cultures for medical purposes; Therapeutic products, namely, antibodies, proteins and peptide therapeutics for treating cancer and oncological conditions; Vaccine preparations; Medical assays for testing of body fluids
42 Pharmaceutical product development services; Pharmaceutical product evaluation services; Pharmaceutical research and development; Providing medical and scientific research information in the field of pharmaceuticals and clinical trials; Research and development of pharmaceuticals for the treatment of cancer and oncological conditions; Research and development of vaccines and medicines; Technical research in the field of pharmaceutical studies; Development of computer platform technology, namely, development of cancer immunotherapy software platforms for manufacturing therapeutics; Consulting services for others in the field of design, planning, and implementation of clinical trials; Information technology platform as Service (PaaS) featuring computer software platforms for cancer diagnosis and analysis of cancer symptoms and cancer treatment, in the medical field; Electronic data storage; Providing a bioinformatics platform as a service (PAAS) featuring computer software platforms for sequence data analysis in the field of manufacturing therapeutics; Medical and scientific research information in the field of cell therapy; Scientific research and analysis for medical purposes in the field of cancer, oncology and clinical trials

Trademark Events
Apr 3, 2024
Notice Of Approval Of Extension Request E-Mailed
Apr 2, 2024
Sou Extension 1 Granted
Apr 2, 2024
Sou Extension 1 Filed
Apr 2, 2024
Sou Teas Extension Received
Oct 3, 2023
Noa E-Mailed - Sou Required From Applicant
Aug 8, 2023
Official Gazette Publication Confirmation E-Mailed
Aug 8, 2023
Published For Opposition
Jul 19, 2023
Notification Of Notice Of Publication E-Mailed
Jul 6, 2023
Approved For Pub - Principal Register
Mar 28, 2023
Suspension Checked - To Attorney For Action
Aug 12, 2022
Report Completed Suspension Check Case Still Suspended
Feb 4, 2022
Report Completed Suspension Check Case Still Suspended
Jul 26, 2021
Notification Of Letter Of Suspension E-Mailed
Jul 26, 2021
Letter Of Suspension E-Mailed
Jul 26, 2021
Suspension Letter Written
Jun 21, 2021
Assigned To Examiner
Feb 3, 2021
Teas/Email Correspondence Entered
Feb 3, 2021
Correspondence Received In Law Office
Feb 3, 2021
Teas Response To Office Action Received
Aug 4, 2020
Notification Of Non-Final Action E-Mailed
Aug 4, 2020
Non-Final Action E-Mailed
Aug 4, 2020
Non-Final Action Written
Jul 29, 2020
Assigned To Examiner
May 15, 2020
New Application Office Supplied Data Entered
May 7, 2020
New Application Entered

Trademark Alertz updated from USPTO on 2030-01-24